Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001493152-24-044792
Filing Date
2024-11-12
Accepted
2024-11-12 16:30:49
Documents
60
Period of Report
2024-09-30

Document Format Files

Seq Description Document Type Size
1 form10-q.htm   iXBRL 10-Q 672719
2 ex31-1.htm EX-31.1 18335
3 ex31-2.htm EX-31.2 18771
4 ex32-1.htm EX-32.1 10639
  Complete submission text file 0001493152-24-044792.txt   4007581

Data Files

Seq Description Document Type Size
5 XBRL SCHEMA FILE impb-20240930.xsd EX-101.SCH 29949
6 XBRL CALCULATION FILE impb-20240930_cal.xml EX-101.CAL 44767
7 XBRL DEFINITION FILE impb-20240930_def.xml EX-101.DEF 121520
8 XBRL LABEL FILE impb-20240930_lab.xml EX-101.LAB 260579
9 XBRL PRESENTATION FILE impb-20240930_pre.xml EX-101.PRE 214340
63 EXTRACTED XBRL INSTANCE DOCUMENT form10-q_htm.xml XML 498389
Mailing Address 1400 BROADFIELD BLVD. SUITE 130 HOUSTON TX 77084
Business Address 1400 BROADFIELD BLVD. SUITE 130 HOUSTON TX 77084 585 232 1500
IMPACT BIOMEDICAL INC. (Filer) CIK: 0001834105 (see all company filings)

EIN.: 853926944 | State of Incorp.: NV | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-42212 | Film No.: 241448930
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)